KYV-201 / Kyverna, Intellia Therap - LARVOL DELTA

Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease (ACR Convergence 2024) - "KYV-201 combines the same fully human anti-CD19 CAR construct as KYV-101 (a first-in-class autologous CAR T-cell therapy being investigated in patients with autoimmune disease) with a differentiated allogeneic platform developed by Intellia Therapeutics involving selected CRISPR/Cas9-mediated gene edits. The preclinical and drug product characterization data generated for KYV-201 demonstrate the functionality and safety necessary to advance to first-in-human studies, bringing the promise of allogeneic anti-CD19 CAR T cells for autoimmune diseases closer to fruition. A phase 1, open-label, multicenter study of the safety, tolerability, and clinical activity of KYV-201 in refractory lupus nephritis is planned."

CAR T-Cell Therapy • Preclinical • Glomerulonephritis • Graft versus Host Disease • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

PRECLINICAL DEVELOPMENT OF KYV-201, AN INVESTIGATIONAL ALLOGENEIC ANTI-CD19 CAR T CELL FOR THE TREATMENT OF AUTOIMMUNE DISEASE (EULAR 2024) - "KYV-201 combines the same fully human anti-CD19 CAR construct as KYV-101, an autologous CAR T-cell therapy being studied in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, with a differentiated allogeneic platform developed by Intellia Therapeutics involving selected CRISPR/Cas9-mediated gene edits[2,5]. The preclinical data generated for KYV-201 demonstrates the functionality and safety necessary to advance to first-in-human studies, bringing the promise of allogeneic CD19 CAR T cells for autoimmune diseases closer to fruition."

CAR T-Cell Therapy • Preclinical • CNS Disorders • Glomerulonephritis • Graft versus Host Disease • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Multiple Sclerosis • Myasthenia Gravis • Nephrology • Scleroderma • Systemic Sclerosis

Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases (ASGCT 2024) - "KYV-201 combines the same fully human anti-CD19 CAR construct as KYV-101, an autologous CAR T-cell therapy being studied in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, with a differentiated allogeneic platform developed by Intellia Therapeutics involving selected CRISPR/Cas9-mediated gene edits (Blarcom TV, CAR TCR Summit. The preclinical data generated for KYV-201 demonstrates the functionality and safety necessary to advance to first-in-human studies, bringing the promise of allogeneic CD19 CAR T cells for autoimmune diseases closer to fruition."

CAR T-Cell Therapy • Preclinical • CNS Disorders • Fibrosis • Glomerulonephritis • Graft versus Host Disease • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Multiple Sclerosis • Myasthenia Gravis • Nephrology • Oncology • Scleroderma • Systemic Sclerosis

"Anyone know the source of Kyverna's KYV-101 & KYV-201? https://t.co/TBwc2DGCFN" (@JacobPlieth)